CDKL1

Summary

CDKL1 (cyclin dependent kinase like 1, HGNC:1781) is a protein-coding gene on chromosome 14q21.3, encoding Cyclin-dependent kinase-like 1 (Q00532).

This gene product is a member of a large family of CDC2-related serine/threonine protein kinases that accumulates primarily in the nucleus.

Source: NCBI Gene 8814 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 51 total
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_004196

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1781
Approved symbol	CDKL1
Name	cyclin dependent kinase like 1
Location	14q21.3
Locus type	gene with protein product
Status	Approved
Aliases	KKIALRE
Ensembl gene	ENSG00000100490
Ensembl biotype	protein_coding
OMIM	603441
Entrez	8814

Gene structure

Transcript identifiers

Ensembl transcripts: 16 — 9 protein_coding, 6 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000216378, ENST00000356146, ENST00000395834, ENST00000525911, ENST00000528197, ENST00000529347, ENST00000530553, ENST00000531052, ENST00000534267, ENST00000534566, ENST00000542671, ENST00000906201, ENST00000906202, ENST00000941216, ENST00000941217, ENST00000941218

RefSeq mRNA: 13 — MANE Select: NM_004196 NM_001282236, NM_001367064, NM_001367065, NM_001423761, NM_001423762, NM_001423763, NM_001423764, NM_001423765, NM_001423766, NM_001423767, NM_001423768, NM_001423769, NM_004196

CCDS: CCDS73637, CCDS9699

Canonical transcript exons

ENST00000395834 — 10 exons

Exon	Start	End
ENSE00000656884	50332262	50332432
ENSE00000656890	50334565	50334621
ENSE00001523003	50326265	50330181
ENSE00002167780	50395701	50396329
ENSE00003466584	50344986	50345058
ENSE00003484767	50359028	50359149
ENSE00003533475	50342132	50342222
ENSE00003560065	50341032	50341232
ENSE00003679240	50338947	50339029
ENSE00003914123	50396824	50396881

Expression profiles

Bgee: expression breadth ubiquitous, 195 present calls, max score 94.62.

FANTOM5 (CAGE): breadth broad, TPM avg 1.5182 / max 54.2742, expressed in 704 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
143149	1.2540	605
143150	0.2548	107
143148	0.0094	5

Top tissues by expression

287 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	94.62	gold quality
calcaneal tendon	UBERON:0003701	90.38	gold quality
endocervix	UBERON:0000458	89.66	gold quality
body of uterus	UBERON:0009853	89.50	gold quality
ectocervix	UBERON:0012249	87.31	gold quality
colonic epithelium	UBERON:0000397	86.98	gold quality
adrenal tissue	UBERON:0018303	86.02	gold quality
metanephros cortex	UBERON:0010533	85.87	gold quality
muscle layer of sigmoid colon	UBERON:0035805	85.83	gold quality
right lobe of thyroid gland	UBERON:0001119	85.76	gold quality
left ovary	UBERON:0002119	85.66	gold quality
monocyte	CL:0000576	85.27	gold quality
mononuclear cell	CL:0000842	85.08	gold quality
rectum	UBERON:0001052	85.00	gold quality
right lung	UBERON:0002167	84.90	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	84.59	gold quality
left lobe of thyroid gland	UBERON:0001120	84.55	gold quality
right ovary	UBERON:0002118	84.49	gold quality
leukocyte	CL:0000738	84.46	gold quality
tendon	UBERON:0000043	84.17	gold quality
thyroid gland	UBERON:0002046	83.39	gold quality
sigmoid colon	UBERON:0001159	82.80	gold quality
Brodmann (1909) area 9	UBERON:0013540	82.74	gold quality
right frontal lobe	UBERON:0002810	82.40	gold quality
transverse colon	UBERON:0001157	81.72	gold quality
ovary	UBERON:0000992	81.54	gold quality
vagina	UBERON:0000996	81.47	gold quality
upper lobe of left lung	UBERON:0008952	81.43	gold quality
left uterine tube	UBERON:0001303	81.35	gold quality
tibial nerve	UBERON:0001323	80.98	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.46
E-MTAB-6678	no	3.05

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

41 targeting CDKL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-1250-3P	99.96	70.04	4038
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-1305	99.91	71.43	3443
HSA-MIR-329-3P	99.91	66.56	1234
HSA-MIR-362-3P	99.91	66.38	1267
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-8063	99.91	69.76	3146
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-4716-3P	99.69	66.73	1022
HSA-MIR-651-5P	99.64	68.49	1104
HSA-MIR-7150	99.62	66.80	1322
HSA-MIR-940	99.37	66.14	2064
HSA-MIR-6808-5P	99.31	66.23	2150
HSA-MIR-6893-5P	99.31	66.25	2119
HSA-MIR-183-5P	99.31	72.27	1164
HSA-MIR-5583-3P	99.06	65.68	1018
HSA-MIR-625-5P	99.02	68.64	2031
HSA-MIR-513B-3P	98.76	68.12	1577
HSA-MIR-6868-3P	98.63	69.64	2259
HSA-MIR-3135B	98.61	65.33	1470

Literature-anchored findings (GeneRIF, showing 5)

• High expression of CDKL1 protein was associated with gastric cancer. (PMID:22369697)
• CDKL1 was overexpressed in breast cancer patients and had a positive detection efficiency of 77% (144/186). (PMID:22804458)
• Chk1 directly interacts with MYPT1 and preferentially phosphorylates MYPT1 at Ser20, which is essential for MYPT1-PP1cbeta interaction and subsequent Plk1 dephosphorylation. (PMID:29262732)
• CDKL1 overexpression decreased the chemosensitivity of oral squamous cell carcinoma cells to hydroxycamptothecin. (PMID:30802495)
• Egr1 inhibits colon cancer cell proliferation, migration and invasion via regulating CDKL1 at the transcriptional level. (PMID:34165179)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cdkl1	ENSDARG00000017329
mus_musculus	Cdkl1	ENSMUSG00000020990
rattus_norvegicus	Cdkl1	ENSRNOG00000038720

Paralogs (26): CDKL3 (ENSG00000006837), CDKL5 (ENSG00000008086), CDK11A (ENSG00000008128), CDK14 (ENSG00000058091), CDK17 (ENSG00000059758), CDK13 (ENSG00000065883), CDK16 (ENSG00000102225), CDK6 (ENSG00000105810), PRP4K (ENSG00000112739), CDK18 (ENSG00000117266), CDK2 (ENSG00000123374), CDK8 (ENSG00000132964), CDK7 (ENSG00000134058), CDK4 (ENSG00000135446), CDK9 (ENSG00000136807), CDK15 (ENSG00000138395), CDKL2 (ENSG00000138769), CDK19 (ENSG00000155111), CDK20 (ENSG00000156345), CDK5 (ENSG00000164885), CDK12 (ENSG00000167258), CDK1 (ENSG00000170312), CDK10 (ENSG00000185324), CDKL4 (ENSG00000205111), CDK11B (ENSG00000248333), CDK3 (ENSG00000250506)

Protein

Protein identifiers

Cyclin-dependent kinase-like 1 — Q00532 (reviewed: Q00532)

Alternative names: Protein kinase p42 KKIALRE, Serine/threonine-protein kinase KKIALRE

All UniProt accessions (5): Q00532, A0A5H1ZRP5, A0A9S7JKS7, H0YCE5, H0YE65

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Cytoplasm. Nucleus.

Tissue specificity. Highly expressed in kidney, and to a lower extent in ovary.

Domain organisation. The [NKR]KIAxRE motif seems to be a cyclin-binding region.

Similarity. Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.

Isoforms (3)

UniProt ID	Names	Canonical?
Q00532-1	1	yes
Q00532-2	2
Q00532-3	3

RefSeq proteins (13): NP_001269165, NP_001353993, NP_001353994, NP_001410690, NP_001410691, NP_001410692, NP_001410693, NP_001410694, NP_001410695, NP_001410696, NP_001410697, NP_001410698, NP_004187* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR050108	CDK	Family

Pfam: PF00069

Enzyme classification (BRENDA):

• EC 2.7.11.22 — cyclin-dependent kinase (BRENDA: 49 organisms, 441 substrates, 555 inhibitors, 8 Km, 4 kcat entries)

Substrate kinetics (BRENDA)

4 substrates with measured Km, best-characterized 4. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ADAQHATPPKKKRKVEDPKDF	0.046–0.521	2
ATP	0.0052–0.017	2
FIN1	0.003	1
PKTPKKAKKL	0.0029	1

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (41 total): helix 14, strand 8, splice variant 6, sequence variant 4, turn 2, binding site 2, chain 1, domain 1, sequence conflict 1, short sequence motif 1, active site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
4AGU	X-RAY DIFFRACTION	2.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q00532-F1	82.09	0.64

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 126 (proton acceptor)

Ligand- & substrate-binding residues (2): 10–18; 33

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 108 (showing top): GOBP_REGULATION_OF_CELLULAR_COMPONENT_BIOGENESIS, MODULE_70, GOBP_REGULATION_OF_CELL_PROJECTION_ORGANIZATION, GOBP_CILIUM_ORGANIZATION, GOBP_REGULATION_OF_CELL_CYCLE, WTGAAAT_UNKNOWN, SCHAEFFER_PROSTATE_DEVELOPMENT_48HR_DN, GOBP_ORGANELLE_ASSEMBLY, SABATES_COLORECTAL_ADENOMA_DN, GOBP_REGULATION_OF_CILIUM_ASSEMBLY, SENESE_HDAC1_TARGETS_UP, GOBP_CELL_PROJECTION_ORGANIZATION, GOBP_REGULATION_OF_CELL_PROJECTION_ASSEMBLY, GOBP_REGULATION_OF_ORGANELLE_ASSEMBLY, SCHLOSSER_SERUM_RESPONSE_UP

GO Biological Process (4): protein phosphorylation (GO:0006468), heart development (GO:0007507), regulation of cilium assembly (GO:1902017), regulation of cell cycle (GO:0051726)

GO Molecular Function (8): protein serine/threonine kinase activity (GO:0004674), cyclin-dependent protein serine/threonine kinase activity (GO:0004693), ATP binding (GO:0005524), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), kinase activity (GO:0016301), transferase activity (GO:0016740)

GO Cellular Component (7): nucleus (GO:0005634), nucleoplasm (GO:0005654), cytoplasm (GO:0005737), centriole (GO:0005814), ciliary transition zone (GO:0035869), extracellular exosome (GO:0070062), sperm midpiece (GO:0097225)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
protein kinase activity	2
phosphorylation	1
protein modification process	1
animal organ development	1
circulatory system development	1
cilium assembly	1
regulation of plasma membrane bounded cell projection assembly	1
regulation of organelle assembly	1
cell cycle	1
regulation of cellular process	1
protein serine/threonine kinase activity	1
cyclin-dependent protein kinase activity	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
intracellular anatomical structure	1
microtubule organizing center	1
intracellular membraneless organelle	1
cilium	1
extracellular vesicle	1
sperm flagellum	1

Protein interactions and networks

STRING

608 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDKL1	PCDHB1	Q9Y5F3	530
CDKL1	EGF	P01133	491
CDKL1	TMEM218	A2RU14	453
CDKL1	WDFY2	Q96P53	440
CDKL1	PIP4K2B	P78356	419
CDKL1	DRC1	Q96MC2	405
CDKL1	PCDH7	O60245	396
CDKL1	PIP5K1B	P78518	392
CDKL1	PI4KA	P42356	390
CDKL1	YWHAG	P35214	387
CDKL1	LRRK1	Q38SD2	377
CDKL1	YWHAB	P31946	371
CDKL1	PRKCG	P05129	360
CDKL1	MAP3K14	Q99558	359
CDKL1	RPS6KB1	P23443	357

IntAct

11 interactions, top by confidence:

A	B	Type	Score
CDKL1	FKBP5	psi-mi:“MI:0914”(association)	0.640
CDKL1	TRIP6	psi-mi:“MI:0914”(association)	0.530
FOXR1	SMARCA5	psi-mi:“MI:0914”(association)	0.350
KATNBL1	MACF1	psi-mi:“MI:0914”(association)	0.350
CDKL1	SUPT5H	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
CDKL1	ACACB	psi-mi:“MI:0914”(association)	0.350
CDKL1	EDIL3	psi-mi:“MI:0914”(association)	0.350
CDKL1	cheA	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (37): HSP90AA5P (Affinity Capture-MS), FKBP5 (Affinity Capture-MS), CDC37 (Affinity Capture-MS), SIRT1 (Affinity Capture-MS), SUPT5H (Affinity Capture-MS), TRIP6 (Affinity Capture-MS), CDKL1 (Affinity Capture-MS), FKBP5 (Affinity Capture-MS), HSP90AB3P (Affinity Capture-MS), SIRT1 (Affinity Capture-MS), CDKL4 (Affinity Capture-MS), HSP90AA5P (Affinity Capture-MS), HSP90AB4P (Affinity Capture-MS), TRIP6 (Affinity Capture-MS), ANKRD28 (Affinity Capture-MS)

ESM2 similar proteins: A4IIW7, A8X5H5, B0VXE8, B0VXL7, B6A7Q3, G4NH08, G5EBT1, O04160, O23145, O44514, P18266, P21965, P38615, P43288, P43289, P49841, P51137, P51138, P51139, Q00532, Q09595, Q10452, Q11179, Q12222, Q388M1, Q39010, Q39011, Q39012, Q39019, Q3S406, Q3TZA2, Q40518, Q5MAI5, Q5YJC2, Q5Z7J0, Q60EZ2, Q6AXJ9, Q6DJM7, Q8CEQ0, Q8MXI4

Diamond homologs: A2X6X1, A2XFC8, A2XUW1, A2YCH5, A8WIP6, B0Y8W7, B3WFY8, G4N0Z0, G4NH08, G5EFV5, O04160, O23145, O42376, O42781, O80345, P16892, P18266, P20793, P20794, P21127, P23573, P24788, P27638, P38615, P39073, P43288, P43289, P43294, P46892, P47812, P49841, P51136, P51137, P51138, P51139, P54665, P54666, Q00532, Q00859, Q03957

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
CDKL1	“up-regulates activity”	CDKN2B	phosphorylation
CDKL1	“up-regulates activity”	RB1	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

51 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	40
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1707 predictions. Top by Δscore:

Variant	Effect	Δscore
14:50330182:C:CC	acceptor_gain	1.0000
14:50332312:T:TA	donor_gain	1.0000
14:50339028:CCCTT:C	acceptor_gain	1.0000
14:50339029:CCTT:C	acceptor_gain	1.0000
14:50341238:CAG:C	acceptor_gain	1.0000
14:50341239:A:T	acceptor_gain	1.0000
14:50341243:A:C	acceptor_gain	1.0000
14:50341249:C:CT	acceptor_gain	1.0000
14:50341250:A:AC	acceptor_gain	1.0000
14:50341250:A:C	acceptor_gain	1.0000
14:50342124:ATACT:A	donor_loss	1.0000
14:50342126:AC:A	donor_loss	1.0000
14:50342127:CTC:C	donor_loss	1.0000
14:50342127:CTCA:C	donor_gain	1.0000
14:50342128:TCA:T	donor_loss	1.0000
14:50342129:CA:C	donor_loss	1.0000
14:50342130:A:AC	donor_gain	1.0000
14:50342130:ACT:A	donor_gain	1.0000
14:50342130:ACTC:A	donor_loss	1.0000
14:50342131:C:A	donor_loss	1.0000
14:50342131:C:CA	donor_gain	1.0000
14:50342131:CT:C	donor_gain	1.0000
14:50342131:CTC:C	donor_gain	1.0000
14:50342131:CTCA:C	donor_gain	1.0000
14:50342131:CTCAA:C	donor_gain	1.0000
14:50342134:AAAAG:A	donor_gain	1.0000
14:50342218:ATGCA:A	acceptor_gain	1.0000
14:50342219:TGCA:T	acceptor_gain	1.0000
14:50342220:GCA:G	acceptor_gain	1.0000
14:50342221:CA:C	acceptor_gain	1.0000

AlphaMissense

2366 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:50341131:A:G	W187R	1.000
14:50341131:A:T	W187R	1.000
14:50342154:G:C	D145E	1.000
14:50342154:G:T	D145E	1.000
14:50342155:T:A	D145V	1.000
14:50342155:T:G	D145A	1.000
14:50342209:T:A	D127V	1.000
14:50342209:T:G	D127A	1.000
14:50342212:C:A	R126I	1.000
14:50395770:C:A	K34N	1.000
14:50395770:C:G	K34N	1.000
14:50395777:G:T	A32D	1.000
14:50332403:C:A	R276S	0.999
14:50332403:C:G	R276S	0.999
14:50341083:A:G	W203R	0.999
14:50341083:A:T	W203R	0.999
14:50341103:A:G	L196P	0.999
14:50341121:C:T	G190D	0.999
14:50341172:A:G	L173P	0.999
14:50341184:C:G	R169P	0.999
14:50342143:G:T	A149D	0.999
14:50342149:C:T	G147E	0.999
14:50342155:T:C	D145G	0.999
14:50342156:C:G	D145H	0.999
14:50342157:A:C	C144W	0.999
14:50342158:C:T	C144Y	0.999
14:50342188:A:G	L134P	0.999
14:50342193:A:C	N132K	0.999
14:50342193:A:T	N132K	0.999
14:50342202:C:A	K129N	0.999

dbSNP variants (sampled 300 via entrez): RS1000093670 (14:50348568 C>A,G), RS1000154456 (14:50389910 G>A), RS1000157483 (14:50342285 C>G), RS1000160084 (14:50332808 A>G), RS1000176806 (14:50365838 G>C), RS1000193871 (14:50386078 T>C), RS1000369654 (14:50398208 T>C), RS1000422666 (14:50392603 C>T), RS1000427337 (14:50378607 C>A), RS1000457628 (14:50354560 A>C), RS1000580135 (14:50354267 G>A,C), RS1000586221 (14:50367331 A>C), RS1000614509 (14:50380626 T>A), RS1000754583 (14:50328706 T>C), RS1000774196 (14:50349377 C>G)

Disease associations

OMIM: gene MIM:603441 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST000579_40	Cognitive performance	4.000000e-06
GCST002312_10	Periodontal disease-related phenotype (Socransky)	8.000000e-06
GCST002935_6	Lead levels	8.000000e-07
GCST007267_37	Systolic blood pressure	2.000000e-16
GCST90002390_262	Mean corpuscular hemoglobin	1.000000e-10
GCST90002392_449	Mean corpuscular volume	9.000000e-10
GCST90011899_49	Aspartate aminotransferase levels	3.000000e-13

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0003926	neuropsychological test
EFO:0006335	systolic blood pressure
EFO:0004527	mean corpuscular hemoglobin
EFO:0004736	aspartate aminotransferase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5789 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,213 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL603469	LESTAURTINIB	3
CHEMBL475251	R-406	2	762
CHEMBL574738	AST-487	1	451

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — Cyclin-dependent kinase-like (CDKL) family

Most potent curated ligand interactions (1 total), top 1:

Ligand	Action	Affinity	Parameter
compound 9b [PMID: 18986805]	Inhibition	7.22	pIC50

ChEMBL bioactivities

6 potent at pChembl≥5 of 6 total, top 6 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.89	Kd	13	nM	AST-487
7.22	IC50	60	nM	CHEMBL455428
6.48	Kd	330	nM	STAUROSPORINE
6.31	Kd	490	nM	LESTAURTINIB
6.00	IC50	1000	nM	TP-030n
5.68	Kd	2100	nM	R-406

PubChem BioAssay actives

5 with measured affinity, of 278 total; 5 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea	624941: Binding constant for CDKL1 kinase domain	kd	0.0130	uM
2-fluoro-N-methyl-4-[[4-(2-methyl-3-propan-2-ylimidazol-4-yl)pyrimidin-2-yl]amino]benzamide	410887: Inhibition of CDK1	ic50	0.0600	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	624941: Binding constant for CDKL1 kinase domain	kd	0.3300	uM
(15S,16S,18R)-16-hydroxy-16-(hydroxymethyl)-15-methyl-28-oxa-4,14,19-triazaoctacyclo[12.11.2.115,18.02,6.07,27.08,13.019,26.020,25]octacosa-1,6,8,10,12,20,22,24,26-nonaen-3-one	624941: Binding constant for CDKL1 kinase domain	kd	0.4900	uM
6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one	624941: Binding constant for CDKL1 kinase domain	kd	2.1000	uM

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	increases expression, increases methylation	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
FR900359	increases phosphorylation	1
triphenyl phosphate	affects expression	1
bisphenol A	increases expression	1
methylselenic acid	decreases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
sodium arsenite	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
(+)-JQ1 compound	decreases expression	1
Sunitinib	decreases expression	1
Acetylglucosamine	decreases expression	1
Cisplatin	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Urethane	decreases expression	1
Okadaic Acid	increases expression	1
Copper Sulfate	decreases expression	1

ChEMBL screening assays

94 unique, capped per target: 94 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1022595	Binding	Inhibition of CDK1	Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors. — Bioorg Med Chem Lett

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1N6	Abcam HeLa CDKL1 KO	Cancer cell line	Female
CVCL_SI44	HAP1 CDKL1 (-) 1	Cancer cell line	Male
CVCL_SI45	HAP1 CDKL1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.